On November 3, 2022 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reported that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting from December 10-13, 2022 (Press release, Genentech, NOV 3, 2022, View Source [SID1234623027]). The data to be presented span numerous blood diseases, including hemophilia A, paroxysmal nocturnal hemoglobinuria (PNH), and various types of blood cancers, including non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Genentech’s approved and investigational medicines will be featured in more than 50 abstracts, including more than 15 oral presentations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data we are presenting reinforce our ongoing commitment to redefining treatment paradigms, improving on existing standards of care and addressing a diversity of patient and healthcare system needs."
Tweet this
"We continually strive to improve patient outcomes by exploring new treatment options across blood disorders, such as lymphomas and rare blood diseases, where unmet needs remain high," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "The data we are presenting reinforce our ongoing commitment to redefining treatment paradigms, improving on existing standards of care and addressing a diversity of patient and healthcare system needs."
Genentech’s Continued Commitment to Reinforcing Strength of Current Portfolio
With 25 years of expertise in blood diseases, Genentech has developed new medicines that changed the standard of care in several blood disorders with high unmet need. The data at this year’s meeting exemplify Genentech’s commitment to investing in its current portfolio to further improve patient outcomes.
Interim data from the Phase III HAVEN 7 study reinforce the efficacy and safety of Hemlibra (emicizumab-kxwh) in infants with severe hemophilia A without factor VIII inhibitors. For this population, early prophylaxis may prevent long-term damage to joints and muscles and potentially reduce the risk of intracranial hemorrhage, which can be life-threatening.
New data evaluating Polivy (polatuzumab vedotin-piiq) that underscore the potential impact of this treatment for the diffuse large B-cell lymphoma (DLBCL) patient community will be shared at the meeting. Health-related quality of life (HRQoL) data from the Phase III POLARIX study will be presented, highlighting the potential impact of Polivy in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) on reducing the need for subsequent treatments in people with previously untreated DLBCL, a population where multiple subsequent treatments can be a significant treatment burden. Based on data from the POLARIX study, this Polivy combination has been approved in the EU and recently, Japan, for the treatment of adult patients with previously untreated DLBCL.
Genentech is presenting updated data from the broadest and most comprehensive CD20xCD3 bispecific antibody development program in the industry. This aims to provide off-the-shelf, fixed-duration treatment options, which address the unique and diverse needs of people with blood cancers. Data include updated analyses for mosunetuzumab, the first CD20xCD3 T-cell engaging bispecific antibody approved by the European Commission to treat follicular lymphoma (FL), and glofitamab, for which data have been submitted for approval to the European Medicines Agency, and submissions to additional health authorities worldwide, including the U.S. Food and Drug Administration (FDA), are ongoing.
An updated analysis from the pivotal Phase II GO29781 study of mosunetuzumab in people with relapsed or refractory (R/R) FL after two or more prior therapies will show continued durable responses across multiple key efficacy endpoints in addition to offering the potential to be administered in an outpatient setting. In addition, studies evaluating mosunetuzumab as a monotherapy and in novel combinations for the treatment of DLBCL in earlier lines of treatment will be presented, highlighting the potential of mosunetuzumab in other settings.
Updated results from the Phase II NP30179 study will show a fixed course of glofitamab monotherapy can deliver durable complete responses in people with heavily pre-treated aggressive lymphomas. Results from the pivotal R/R DLBCL cohort indicate patients can maintain durable responses following fixed-duration treatment with glofitamab, potentially allowing them to benefit from a treatment-free period.
Exploring and Innovating in New Areas of Unmet Need
Genentech is applying its scientific expertise to expand its hematology clinical development program by exploring additional blood diseases and bringing innovations that address the various needs of patients in areas of high unmet need.
The first Phase III clinical data for crovalimab from the COMMODORE 3 study in China will be presented at ASH (Free ASH Whitepaper). These data demonstrate that crovalimab met the co-primary efficacy endpoints, suggesting that crovalimab is efficacious and well-tolerated in people with PNH, a rare and life-threatening blood condition, where healthy red blood cells are targeted and destroyed by the body’s complement system. There are currently no effective treatment options for PNH broadly available in China.
Spark Therapeutics, a member of the Roche Group, will share updated long-term follow-up data from the ongoing Phase I/II clinical trial of SPK-8011, an investigational AAV-based gene therapy being developed for the treatment of hemophilia A. The acquisition of Spark Therapeutics brought new capabilities in hemophilia A to address the high unmet medical need for people living with this disease and endeavor to create additional benefit beyond current treatment options.
Positive data on cevostamab will be presented at ASH (Free ASH Whitepaper), including data from the Phase I GO39775 study, which suggest that patients with heavily pre-treated multiple myeloma can maintain durable responses with fixed-duration cevostamab. Additionally, Phase I data from Genentech’s GPRC5DxCD3 T-cell engaging bispecific antibody, RG6234, showing encouraging preliminary activity in people with R/R multiple myeloma, will be presented. With this pipeline, Genentech is committed to advancing treatments for multiple myeloma, which remains an incurable disease characterized by multiple relapses.
Further information on the key abstracts featuring Genentech medicines that will be presented at ASH (Free ASH Whitepaper) can be found in the table below.
Follow Genentech on Twitter via @Genentech and LinkedIn and keep up to date with ASH (Free ASH Whitepaper) Annual Meeting news and updates by using the hashtag #ASH22.
Medicine
Abstract title
Abstract number/presentation details
Cevostamab
Pre-treatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
#567 poster presentation
Session: 653
Sunday, December 11, 2022
12:00-1:30 PM CT
Enduring Responses After One-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
#1924 poster presentation
Session: 653
Saturday, December 10, 2022
5:30-7:30 PM CT
Crovalimab
Results From the First Phase 3 Crovalimab (C5-Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
#293 oral presentation
Session: 508
Saturday, December 10, 2022
4:00-5:30 PM CT
Pharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
#1247 poster presentation
Session: 508
Saturday, December 10, 2022
5:30-7:30 PM CT
Glofitamab
Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pre-treated Relapsed or Refractory Mantle Cell Lymphoma
#74 oral presentation
Session: 623
Sunday, December 11, 2022
9:30-11:00 AM CT
Relapse is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
#441 oral presentation
Session: 626
Saturday, December 10, 2022
9:30-11:00 AM CT
Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
#737 oral presentation
Session: 626
Monday, December 12, 2022
10:30 AM-12:00 PM CT
Hemlibra
Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
#187 oral presentation
Session: 322
Saturday, December 10, 2022
2:00-3:30 PM CT
Real-World Safety of Emicizumab: Interim Analysis of the European Hemophilia Safety Surveillance (EUHASS) Database
#192 oral presentation
Session: 322
Saturday, December 10, 2022
2:00-3:30 PM CT
Characteristics and Bleeding Behavior of Females with Mild Hemophilia A: Longitudinal Study from PicnicHealth Hemophilia A Database
#27 oral presentation
Session: 322
Saturday, December 10, 2022
9:30-11:00 AM CT
Emicizumab and Females with Hemophilia A: Case Series from ATHN 7
#1162 poster presentation
Session: 322
Saturday, December 10, 2022
5:30-7:30 PM CT
Characteristics and Healthcare Utilization of Patients with Mild or Moderate Hemophilia A in the US – An Analysis from the PicnicHealth Cohort
#1170 poster presentation
Session: 322
Saturday, December 10, 2022
5:30-7:30 PM CT
Mosunetuzumab
Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma who have Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
#610 oral presentation
Session: 623
Sunday, December 11, 2022
4:30-6:00 PM CT
Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-cell Lymphoma
#738 oral presentation
Session: 626
Monday, December 12, 2022
10:30 AM-12:00 PM CT
Mosunetuzumab with Polatuzumab Vedotin is Effective and has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
#1630 poster presentation
Session: 626
Saturday, December 10, 2022
5:30-7:30 PM CT
SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin versus Rituximab in Combination with Gemcitabine plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
#1637 poster presentation
Session: 626
Saturday, December 10, 2022
5:30-7:30 PM CT
Subcutaneous (SC) Mosunetuzumab is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphoma (B-NHL): Updated Results from a Phase I/II Study
#1628 poster presentation
Session: 626
Saturday, December 10, 2022
5:30-7:30 PM CT
Polivy
Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) by Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
#542 oral presentation
Session: 621
Sunday, December 11, 2022
12:00-1:30 PM CT
Polatuzumab Vedotin plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
#4260 poster presentation
Session: 626
Monday, December 12, 2022
6:00-8:00 PM CT
Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
#3527 poster presentation
Session: 902
Sunday, December 11, 2022
6:00-8:00 PM CT
Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
#2949 poster presentation
Session: 626
Sunday, December 11, 2022
6:00-8:00 PM CT
RG6234
RG6234, a GPRC5DxCD3 T-cell Engaging Bispecific Antibody, is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation study
#161 oral presentation
Session: 653
Saturday, December 10, 2022
12:00-1:30 PM CT
SPK-8011
Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
#783 oral presentation
Session: 801
Monday, December 12, 2022
10:30 AM-12:00 PM CT
Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A
#4783 poster presentation
Session: 801
Monday, December 12, 2022
6:00-8:00 PM CT
The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011
#4779 poster presentation
Session: 801
Monday, December 12, 2022
6:00-8:00 PM CT
About Hemlibra
Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins required to activate the natural coagulation cascade and restore the blood clotting process for hemophilia A patients. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once weekly, every two weeks or every four weeks. Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech.
Hemlibra U.S. Indication
Hemlibra is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.
Important Safety Information
What is the most important information to know about Hemlibra?
Hemlibra increases the potential for blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba) to treat breakthrough bleeds while taking Hemlibra may be at risk of serious side effects related to blood clots.
These serious side effects include:
Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood vessels that may cause harm to one’s kidneys, brain, and other organs
Blood clots (thrombotic events), which may form in blood vessels in the arm, leg, lung, or head
Patients should talk to their doctor about the signs and symptoms of these serious side effects, which can include:
Confusion
Stomach, chest, or back pain
Weakness
Nausea or vomiting
Swelling, pain, or redness
Feeling sick or faint
Decreased urination
Swelling of arms and legs
Yellowing of skin and eyes
Eye pain, swelling, or trouble seeing
Fast heart rate
Numbness in your face
Headache
Shortness of breath
Coughing up blood
If patients experience any of these symptoms during or after treatment with Hemlibra, they should get medical help right away.
Patients should carefully follow their healthcare provider’s instructions regarding when to use an on demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba) is needed, patients should talk to their healthcare provider in case they feel they need more than 100 U/kg of aPCC (Feiba) total.
Patients’ bodies may make antibodies against Hemlibra, which may stop Hemlibra from working properly. Patients should contact their healthcare provider immediately if they notice that Hemlibra has stopped working for them (e.g., increase in bleeds).
The most common side effects of Hemlibra include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of Hemlibra. Patients can speak with their healthcare provider for more information.
What else should patients know about Hemlibra?
Patients should see the detailed "Instructions for Use" that comes with Hemlibra for information on how to prepare and inject a dose of Hemlibra, and how to properly throw away (dispose of) used needles and syringes.
Patients should stop taking their prophylactic bypassing therapy the day before they start Hemlibra
Patients may continue taking their prophylactic factor VIII for the first week of Hemlibra
Hemlibra may interfere with laboratory tests that measure how well blood is clotting and create an inaccurate result. Patients should speak with their healthcare provider about how this may affect their care.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Patients should only use Hemlibra for the condition it was prescribed. Patients should not give Hemlibra to other people, even if they have the same symptoms that they have. It may harm them.
Patients should tell their healthcare provider about all the medicines they take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Patients should keep a list of them to show their healthcare provider and pharmacist.
Before using Hemlibra, patients should tell their healthcare provider about all of their medical conditions, including if they are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.
Since Hemlibra was tested in males, there is no information on whether Hemlibra may impact an unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.
Side effects may be reported to the FDA at (800) FDA-1088 or View Source Side effects may also be reported to Genentech at (888) 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the Hemlibra full Prescribing Information and Medication Guide.
About Polivy (polatuzumab vedotin-piiq)
Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy is designed to bind to CD79b on B cells and destroys them through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Seagen ADC technology and is currently being investigated for the treatment of several types of NHL.
Polivy U.S. Indication
Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least two prior therapies.
The accelerated approval of Polivy is based on a type of response rate. There are ongoing studies to confirm the clinical benefit of Polivy.
Important Safety Information
Possible serious side effects
Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. A patient’s doctor may stop or adjust a patient’s treatment if any serious side effects occur. Patients must contact their healthcare team if there are any signs of these side effects.
Nerve problems in arms and legs: This may happen as early as after the first dose and may worsen with every dose. If a patient already has nerve pain, Polivy may make it worse. The patient’s doctor will monitor for signs and symptoms, such as changes in sense of touch, numbness or tingling in hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to walking patterns
Infusion-related reactions: A patient may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of the infusion
Infections: Patients should contact their healthcare team if they experience a fever of 100.4°F or higher, chills, cough, or pain during urination. Also, a patient’s doctor may give medication before giving Polivy, which may prevent some infections, and monitor blood counts throughout treatment with Polivy. Treatment with Polivy can cause severe low blood cell counts
Rare and serious brain infections: A patient’s doctor will monitor the patient closely for signs and symptoms of these types of infections. Patients should contact their doctor if they experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes
Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy
Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of the skin or the white part of the eyes. Patients may be at higher risk if they already have liver problems or are taking other medication
Side effects seen most often
The most common side effects during treatment were:
Low blood cell counts (platelets, red blood cells, white blood cells)
Nerve problems in arms and legs
Tiredness or lack of energy
Diarrhea
Nausea
Fever
Decreased appetite
Infections
Polivy may not be for everyone. A patient should talk to their doctor if they are:
Pregnant or may be pregnant: Data have shown that Polivy may harm an unborn baby
Planning to become pregnant: Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for at least 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for at least 5 months after their last Polivy treatment
Breastfeeding: Women should not breastfeed while taking Polivy and for at least 2 months after the last dose
These may not be all the side effects. Patients should talk to their healthcare provider for more information about the benefits and risks of Polivy treatment.